DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a report issued on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a report on Thursday, November 14th. Get Our Latest Research Report on DRRX DURECT […]
9 Jan 06:56 · The Markets Daily